Trial Profile
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs SVN53-67-M57-KLH peptide vaccine (Primary) ; Montanide ISA-51; Sargramostim; Temozolomide; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Proof of concept; Therapeutic Use
- 27 Feb 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 09 Jan 2024 According to a MimiVax Media Release, new investments to support clinical development of SurVaxM in glioblastoma was catalyzed by positive results from Phase 2a study of SurVaxM in newly diagnosed glioblastoma.
- 15 Dec 2022 Results published in the MimiVax Media Release